Granite Bio

Executive Summary

Granite Bio is a Swiss private biotechnology company focused on developing first-in-class therapeutic antibodies that deplete pathogenic cells to treat inflammation, autoimmunity, and fibrosis. Founded in 2021, the company is currently in Phase 1 clinical development, leveraging its proprietary platform to target fundamental disease mechanisms. With a strategy centered on depleting disease-causing cell populations, Granite Bio aims to offer transformative therapies for chronic inflammatory and fibrotic conditions, addressing significant unmet medical needs. The company's early-stage pipeline, though not publicly detailed, holds promise for novel mechanisms of action in immunology and fibrotic diseases. As a private entity, Granite Bio relies on venture funding and strategic partnerships to advance its programs. The upcoming catalysts include initial Phase 1 data readouts, which could validate its approach and de-risk further development. Given the early stage, the conviction score is moderate, reflecting the potential of its differentiated technology balanced against typical clinical and regulatory risks.

Upcoming Catalysts (preview)

• Q4 2026Phase 1 interim data for lead antibody candidate50% success
• Q2 2027IND filing for second program70% success
• H2 2026Partnership or licensing deal for fibrosis indication30% success